United Therapeutics (NASDAQ:UTHR) CEO Sells $5,212,555.00 in Stock

Posted by Francis Steltz on Jun 28th, 2026

United Therapeutics Corporation (NASDAQ:UTHR – Get Free Report) CEO Martine Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $548.69, for a total value of $5,212,555.00. Following the completion of the sale, the chief executive officer directly owned 40,513 shares in the company, valued at $22,229,077.97. This represents a 19.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

United Therapeutics Stock Performance

NASDAQ UTHR opened at $542.66 on Friday. The business has a fifty day moving average price of $561.23 and a 200 day moving average price of $525.58. United Therapeutics Corporation has a one year low of $272.12 and a one year high of $609.35. The company has a market cap of $23.04 billion, a P/E ratio of 20.03, a P/E/G ratio of 1.79 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR – Get Free Report) last released its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The business had revenue of $781.50 million for the quarter, compared to analysts’ expectations of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.United Therapeutics’s quarterly revenue was down 1.6% compared to the same quarter last year. During the same period in the previous year, the company earned $6.63 EPS. As a group, sell-side analysts predict that United Therapeutics Corporation will post 26.49 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Wellington Management Group LLP increased its holdings in United Therapeutics by 74.5% during the 4th quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock worth $1,189,617,000 after purchasing an additional 1,042,711 shares during the period. Darwin Global Management Ltd. purchased a new stake in shares of United Therapeutics during the third quarter worth approximately $317,617,000. Norges Bank acquired a new stake in United Therapeutics in the fourth quarter valued at approximately $293,418,000. Avoro Capital Advisors LLC raised its holdings in United Therapeutics by 17.3% in the fourth quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock valued at $1,269,803,000 after acquiring an additional 383,838 shares in the last quarter. Finally, Janus Henderson Group PLC lifted its stake in United Therapeutics by 75.1% in the fourth quarter. Janus Henderson Group PLC now owns 796,101 shares of the biotechnology company’s stock worth $387,801,000 after acquiring an additional 341,383 shares during the last quarter. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts have recently weighed in on the company. Cantor Fitzgerald boosted their target price on United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a report on Thursday, March 12th. Raymond James Financial assumed coverage on United Therapeutics in a research note on Friday, April 10th. They issued an “outperform” rating and a $700.00 target price for the company. Bank of America lifted their price target on United Therapeutics from $569.00 to $626.00 and gave the stock a “neutral” rating in a report on Tuesday, March 31st. TD Cowen reissued a “buy” rating on shares of United Therapeutics in a report on Thursday, May 21st. Finally, Wells Fargo & Company upgraded United Therapeutics from an “equal weight” rating to an “overweight” rating and increased their price objective for the stock from $575.00 to $735.00 in a research report on Thursday, May 7th. Eleven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, United Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $619.42.

Read Our Latest Stock Analysis on UTHR

United Therapeutics Company Profile

(Get Free Report)

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.